Name: TBHQ
Brand: Selleck Chemicals
SKU: S4990
Rating: 5 (17 reviews)

Tert-butylhydroquinone (TBHQ) is an antioxidant compound which is used to prevent lipid peroxidation and shows multiple cytoprotective actions. It is an activator of Nrf2.

TBHQ Chemical Structure

CAS: 1948-33-0

Selleck's TBHQ has been cited by 17 publications

Purity & Quality Control

Batch: Purity: 99.82%

99.82

TBHQ Related Products

Choose Selective Nrf2 Inhibitors

Biological Activity

Description

Tert-butylhydroquinone (TBHQ) is an antioxidant compound which is used to prevent lipid peroxidation and shows multiple cytoprotective actions. It is an activator of Nrf2.

Targets

Nrf2 ^[1]

In vitro
In vitro	Tert-butylhydroquinone (tBHQ) is a metabolite of the chemical compound butylated hydroxyanisole and induces Nrf2 activation and conveys protection against hydrogen peroxide, 6-hydroxydopamine, the pesticidal deltamethrin, and other toxicants. tBHQ preferentially alters the redox status in the mitochondrial compartment in HeLa cells. HeLa cells treated with tBHQ show a preferential oxidation of mitochondrial thioredoxin-2 (Trx2), while cellular glutathione and cytosolic thioredoxin-1 are not affected^[1]. In cultured H9c2 cells and primary cardiac myocytes, TBHQ stimulates Akt phosphorylation and suppresses oxidant-induced apoptosis^[2].
Cell Research	Cell lines	HeLa cells
	Concentrations	0-15 μM
	Incubation Time	1 h
	Method	HeLa cells are grown until confluent and loaded with 100 µM DCF in loading medium (DMEM with 1% FBS) for 30 min. Cells are washed and then treated with tBHQ (0-15 μM in DMSO) for 1 h. DCF fluorescence is followed in a fluorometer at 488-nm excitation and 520-nm emission.
Experimental Result Images	Methods	Biomarkers	Images	PMID
	Western blot	c-Fos / p-JunD / JunD p-JNK / JNK / p-ERK / ERK p-AKT / AKT α-Nrf2 / α-AKR1C1		24830941
	Immunofluorescence	HO-1		31333462

In Vivo
In vivo	TBHQ treatment elicits significant cytoprotective actions in different organs under pathological conditions. Systemic or local intra-cerebroventricular treatment with TBHQ in an ischemic stroke model in rats significantly reduces the infarct size and neurological deficits. Administration of TBHQ in rats suppresses renal damage and oxidative stress after ischemia and reperfusion injury. In mice with type 1 diabetes, chronic treatment with TBHQ significantly reduces the degree of glomerular fibrosis and ameliorates proteinuria. TBHQ treatment prevents left ventricular dilatation and cardiac dysfunction induced by transverse aortic constriction (TAC), and decreases the prevalence of myocardial apoptosis. The beneficial effects of TBHQ are associated with an increase in Akt activation, but not related to activations of Nrf2 or AMP-activated protein kinase. TBHQ-induced Akt activation is accompanied by increased phosphorylation of Bad, glycogen synthase kinase-3β (GSK-3β) and mammalian target of rapamycin (mTOR)^[2].
Animal Research	Animal Models	male C57BL/6 mice
	Dosages	ratio of 1% (w/w) with the animal food powder
	Administration	oral

References

Chemical Information & Solubility

Molecular Weight	166.22	Formula	C₁₀H₁₄O₂
CAS No.	1948-33-0	SDF	--
Smiles	CC(C)(C)C1=C(C=CC(=C1)O)O
Storage (From the date of receipt)	3 years-20°Cpowder	Storage of Stock Solutions Aliquot the stock solutions to avoid repeated freeze-thaw cycles	1 year-80°Cin solvent
Storage (From the date of receipt)	3 years-20°Cpowder		1 month-20°Cin solvent

In vitro
Batch:

DMSO : 33 mg/mL ( (198.53 mM)； Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Ethanol : 33 mg/mL

Water : 4 mg/mL

Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.

In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Dilution Calculator Molecular Weight Calculator

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):